Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study

doi:10.3748/wjg.v21.i16.5023

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6558)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

432

WORD

320

HTML

3327

Figures (1-5)

130

Tables (1-2)

121

Sum=4330

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1074

Download

1154

Sum=2228

Apr 28, 2015 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Apr 28, 2015; 21(16): 5023-5031
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.5023

Table 1 Clinical features of patients receiving rabeprazole plus irsogladine maleate (group I) or rabeprazole plus placebo (group P)

	Group I (n = 49)	Group P (n = 48)	P value
Age (yr), mean ± SD	51.1 ± 16.4	51.1 ± 14.8	0.77
Sex, male/female	13/36	19/29	0.17
BMI (kg/m²)	22.4 ± 4.3	21.8 ± 3.1	0.59
Height (cm)	159 ± 7.3	161.5 ± 8.7	0.24
Weight (kg), mean ± SD	57.1 ± 12.2	56.7 ± 8.6	0.63
NERD grade (N/M)	21/28	20/28	0.91
Hiatal hernia (+/-)	11/38	10/38	0.85
Drinking (+/-)	16/33	20/28	0.36
Smoking (+/-)	2/47	9/39	0.05

NERD: Non-erosive reflux disease; BMI: Body mass index.

Citation: Suzuki T, Matsushima M, Masui A, Tsuda S, Imai J, Nakamura J, Tsukune Y, Uchida T, Yuhara H, Igarashi M, Koike J, Mine T. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study. World J Gastroenterol 2015; 21(16): 5023-5031
URL: https://www.wjgnet.com/1007-9327/full/v21/i16/5023.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i16.5023